The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated analysis from NEJ045A study: Safety and efficacy of durvalumab plus carboplatin and etoposide for previously untreated extensive-stage small-cell lung cancer patients with a poor performance status.
 
Tetsuhiko Asao
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Merck; MSD K.K; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Satoshi Watanabe
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Nippon Kayaku
 
Yu Saida
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; MSD
 
Akira Kisohara
No Relationships to Disclose
 
Kazuma Kishi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim
 
Ryo Morita
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Taiho Pharmaceutical
 
Taku Nakagawa
Honoraria - AstraZeneca Japan; Chugai Pharma; Japan Blood Products Organization; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Yoko Tsukita
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly; MSD; Nippon Boehringer Ingelheim; Novartis; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca
Research Funding - Chugai Pharma (Inst); Lilly (Inst)
 
Naoki Furuya
No Relationships to Disclose
 
Taichi Miyawaki
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical
 
Nobuhisa Ishikawa
Speakers' Bureau - AstraZeneca Japan
 
Tadaaki Yamada
Honoraria - Chugai Pharma; Lilly
Research Funding - Ono Pharmaceutical; Takeda
 
Toshiaki Kikuchi
Honoraria - Asahi Kasei; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Gilead Sciences; GlaxoSmithKline; Insmed; Janssen; Japan Blood Products Organization; Kyorin; Kyowa Kirin; MSD; Nippon Kayaku; Nippon Shinyaku; Ono Pharmaceutical; Pfizer; Shionogi; TERUMO; Viatris
Research Funding - Asahi Kasei; Chugai Pharma; Nippon Boehringer Ingelheim; Nippon Kayaku; Nobelpharma; Taiho Pharmaceutical; Teijin Pharma
 
Takahiro Tanaka
No Relationships to Disclose
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Lilly Japan; MSD K.K.; Ono Pharmaceutical; Sanofi
 
Kunihiko Kobayashi
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan
Speakers' Bureau - AstraZeneca; Janssen
Research Funding - Zeria Pharmaceutical Co. (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on Japanese patent # 7422498; Peptide of inhibiting cell migration, cell invasion, and cancer metastasis.
 
Makoto Maemondo
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi-Sankyo; Lilly; Merck Sharp and Dohme; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Boehringer Ingelheim (Inst); Chugai Pharma; Janssen (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)